SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SNY Analysis & Videos »
SNY: Bull or Bear?
Goldman Sachs Targets Allergan as Takeover Candidate
SNY
+13.27%
in
693 days
Filed under: Analyst Upgrades and Downgrades, Allergan (AGN), Stocks to Buy   If you're interested on taking a bet on a potential high-flyer, you might want to take a look at Allergan (AGN).
Goldman Sachs recently said they expect more M&A activity in pharmaceutical and that Allergan is a prime candidate for a takeover. Sanofi-Aventis (SNY) and Eli Lilly & Co. (LLY) are two companies analysts are speculating may be interested in acquiring Allergan. Goldman also upgraded its price target for Allergan on its Conviction Buy List from $78 to $81. <><>Continue reading <>Goldman Sachs Targets Allergan as Tak...
|
Unilife Medical (UNIFF.PK) (UNI.AX) Poised for NASDAQ: UNIS Trading Debut
SNY
|
|
|
-13.88%
in
875 days
<> During the second week of January, Unilife Medical Solutions (ASX: UNI.AX) (OTC: UNIFF.PK) shareholders overwhelmingly voted in favor of the Company’s U.S. relocation. Unilife is now in the final stages of preparation for a NASDAQ: UNIS stock market trading debut, which is expected to occur by the end of February in conjunction with the Company’s re-domiciliation to Central Pennsylvania. Unilife is emerging as a leading innovator in the medical device manufacturing space with a focus on safety syringes and business segments that include pre-filled syringes for pharmaceutical companies to d<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>...
|
Access Pharma (OTC: ACCP.OB): ProLindac Well Positioned as Improved, Safer Platinum Drug
SNY
|
|
|
+0.67%
in
5 days
(closed on 01/12/10)
Access Pharma (OTC: ACCP.OB) announced today that it completed evaluation of the last additional cohort of eight patients for its ongoing study of ProLindac as mono-therapy for ovarian cancer patients who were previously treated with at least two platinum-based anti-cancer regimens. The eight-patient cohort received ProLindac that was manufactured by a new, improved process that is scalable and will be used for future studies and commercialization. This small, pilot study validates the new, scalable manufacturing process for ProLindac that is a key component for partnership discussions and ...
|
Unilife Medical (ASX: UNI.AX) (UNIFF.PK): Recent Sell-Off Unwarranted, Quick Rebound Likely
SNY
|
|
|
+4.62%
in
25 days
(closed on 01/07/10)
Unilife Medical Solutions (ASX: UNI.AX) (OTC: UNIFF.PK) is emerging as a leading innovator in the medical device manufacturing space with a focus on safety syringes and business segments that include pre-filled syringes for pharmaceutical companies to deliver injectable medications, sharps safety devices for healthcare facilities, and contract manufacturing services. <> Last Thursday afternoon, a large block of stock (over 1 million shares) hit the tape, sending Unilife’s primary ASX stock listing from around $1 to 87 cents before recovering about half of this loss and settling <><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>...
|
Cramer on BloggingStocks: Sanofi has lots of upside catalysts
SNY
-9.79%
in
925 days
Filed under: Analyst reports, Pfizer (PFE), Market matters, Bristol-Myers Squibb (BMY), Merck and Co (MRK), Lilly (Eli) (LLY), Deere and Co (DE), Stocks to Buy, Potash Corp. of Saskatchewan (POT) TheStreet.com's Jim Cramer says it looks like the patent worries aren't so dire after all.
Now that we see that health care reform is not going to bring price caps or socialization of medicine, we are beginning to see some real expansion in the drug stocks, including Merck (MRK) (<>Cr...
|
Access Pharma CEO Interview: Updates and Outlook
SNY
|
|
|
+11.50%
in
106 days
(closed on 12/13/09)
<> Corporate Profile has posted a <font> video interview on YouTube </font> with the President and CEO of Access Pharma (ACCP.ob), Jeffrey B. Davis, which summarizes the compelling investment opportunity represented by his Company. Mr. Davis provides an overview of Access Pharma, explaining that it is not a development-stage company because MuGard has already received marketing clearance by the FDA in the U.S. along with similar approvals worldwide and is in the early stages of its global commercial launch. Furthermore, the Company expects multiple catalysts before year-end which have t...
|
FDA Calendar Updates: POZN, AZN, SNY, CEPH, APPY, CYTR
SNY
|
|
|
+17.61%
in
60 days
(closed on 08/29/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-st...
|
Access Pharma (OTC:ACCP): Low Valuation, Big Potential
SNY
|
|
|
+0.24%
in
55 days
(closed on 06/30/09)
With shares of Cell Therapeutics (NASDAQ:CTIC) staging the most astonishing comeback I have ever witnessed while rising from 8 cents at the time of <font> my original article in early February </font> to as high as $1.85 during intraday trading today and closing at $1.27 – I went in search of another out-of-favor name in the cancer biotech space. <> Access Pharma (OTC:ACCP) is an emerging bio-pharma company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to an FDA approved treatment for a side effect of some cancer treatmen...
|
Unilife: Making Syringes Safer, Relocating to U.S.
SNY
|
|
|
+5.63%
in
36 days
(closed on 05/06/09)
For the first time since its public listing in 2002, Unilife Medical Solutions (Australia: UNI.AX) (U.S. ADR: UNIFF.PK) posted a net profit which came in at $11M for the six-month period ending 12/31/08. Unilife posted a 43% increase in revenue to $2.7M, compared to the year-ago period and net income was driven by $23.4M in other income (largely accounted for by a major licensing deal for the Company's pre-filled syringe). The Company ended the year with $10.9M in cash/equivalents and total liabilities of $7.4M ($3.2M current, $4.2M long-term). <> <>http://biomedreport...
|
Updated Clinical Trial and FDA Decision Calendars
SNY
|
|
|
+1.06%
in
11 days
(closed on 03/31/09)
Below is a summary of updates to the BioMedReports.com database of 241 entries included in the FDA and Clinical Trial Calendars. <> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 104 entries through 3/20/09. The FDA Calendar includes the following information: company name, ticker, decision date, and descrip...
|
Updated Clinical Trial and FDA Decision Calendars
SNY
|
|
|
+0.62%
in
3 days
(closed on 03/20/09)
<> <> Updated Clinical Trial and FDA Calendars
Below is a summary of updates to the www.BioMedReports.co <wbr> </wbr> m database of 243 entries included in the FDA and Clinical Trial Calendars.
http://biomedreports <wbr> </wbr> .com/fda-calendar.ht <wbr> </wbr> ml
The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 104 entries through today. The FDA Calend...
|
Eli Lilly Sinks After Hours on Effient Delay
SNY
|
|
|
-19.05%
in
13 days
(closed on 10/11/08)
<> 
Eli Lilly (LLY) and Daiichi Sankyo (Tokyo: 4568) announced on Friday evening that the FDA had not completed its regulatory review for its blood thinner drug, which would go by the brand name of Effient (prasugrel). The FDA previously delayed its decision by three months earlier this summer, but in this case no new deadline was set by the agency. Shares of Eli Lilly slid by about 4% after hours on less than 100,000 shares traded, closing near its 52-week low at $45.01 per share on Friday evening. However, the current sli...
|
Bullish on SNY ...
SNY
|
|
|
+6.11%
in
1367 days
Sanofi-Aventis engages in the research, development, manufacture, and marketing of healthcare products worldwide. It offers products in various therapeutic fields, including cardiovascular, thrombosis, oncology, metabolic disorders, central nervous system, and internal medicine and vaccines. The company�s products include Plavix, an anti-platelet agent for various atherothrombotic conditions; Lovenox, a low molecular weight heparin indicated for prophylaxis and treatment of deep vein thrombosis, and for unstable angina and myocardial infarction; Aprovel and Tritace for hypertension treatm...
|
Sanofi Warrants Cheaper Valuation
SNY
+4.80%
in
1440 days
While valuation on the combined company is reasonable, we would like to see more visibility on some of the patent issues before we recommend buying the shares.
|
People Bullish on SNY
People Bearish on SNY
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Confidence Restored?
- CONFIDENCE RESTORED?
Have we all of the sudden seen a dramatic improvement in confidence? The action over the last 2 days (the best 2 day gain since 1...
|
More Resources
|
About SanofiAventis
- Answers.com
"Sanofi-Aventis (
